Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone. 2021;2022(154):116202.

Google Scholar 

Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832–43.

PubMed  Google Scholar 

Pasricha SR, Tye-Din J, Muckenthaler MU, et al. Iron deficiency. Lancet. 2021;397(10270):233–48.

CAS  PubMed  Google Scholar 

Toblli J, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475.

PubMed  PubMed Central  Google Scholar 

Kennedy NA, Achebe MM, Biggar P, et al. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm. 2023;45(3):604–12.

PubMed  PubMed Central  Google Scholar 

Avni T, Bieber A, Grossman A, et al. The Safety of Intravenous Iron Preparations. Mayo Clin Proc. 2015;90(1):12–23.

PubMed  Google Scholar 

Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187–95.

CAS  PubMed  Google Scholar 

Wolf M, Auerbach M, Kalra PA, et al. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. Am J Hematol. 2021;96(1):E11–5.

CAS  PubMed  Google Scholar 

Anker SD, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436–48.

CAS  PubMed  Google Scholar 

Cunha GJL, Rocha BML, Menezes FL. Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions. Eur J Intern Med. 2018;52:1–7.

CAS  PubMed  Google Scholar 

McMurray JJV, Parfrey PS, Adamson JW, et al. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.

Google Scholar 

Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis. 2022;79(6):868–76.

CAS  PubMed  Google Scholar 

Glaspy JA, Wolf M, Strauss WE. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021;38(7):3531–49.

CAS  PubMed  PubMed Central  Google Scholar 

Schaefer B, Zoller H, Wolf M. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. J Clin Endocrinol Metab. 2022;107(4):1009–19.

PubMed  Google Scholar 

Vilaca T, Velmurugan N, Smith C, et al. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. J Bone Miner Res. 2022;37(6):1188–99.

CAS  PubMed  Google Scholar 

Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: A systematic literature review. Ther Clin Risk Manag. 2020;16:245–59.

CAS  PubMed  PubMed Central  Google Scholar 

Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256–73.

CAS  PubMed  Google Scholar 

Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.

CAS  PubMed  PubMed Central  Google Scholar 

Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16(1):7–19.

CAS  PubMed  Google Scholar 

Cipriani C, Minisola S, Colangelo L, et al. FGF23 functions and disease. Minerva Endocrinol. 2022;47(4):437–48.

Google Scholar 

Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: A downward spiral in kidney disease. Kidney Int. 2011;79(7):715–29.

CAS  PubMed  Google Scholar 

Barthel TK, Mathern DR, Whitfield GK, et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007;103(3–5):381–8.

CAS  PubMed  Google Scholar 

Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–55.

PubMed  PubMed Central  Google Scholar 

Richter B, Faul C. FGF23 actions on target tissues-with and without Klotho. Front Endocrinol (Lausanne). 2018;9. https://doi.org/10.3389/fendo.2018.00189

Czaya B, Faul C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. Int J Mol Sci. 2019;20(17):4195.

PubMed  PubMed Central  Google Scholar 

David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135–46.

CAS  PubMed  PubMed Central  Google Scholar 

Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793–803.

CAS  PubMed  Google Scholar 

Wolf M, Chertow GM, Macdougall IC et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI insight. 2018;3(23). https://doi.org/10.1172/jci.insight.124486

Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab. 2009;94(7):2332–7.

CAS  PubMed  Google Scholar 

Emrich IE, Lizzi F, Siegel JD, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose - The randomized controlled HOMe aFers study. BMC Med. 2020;18(1):1–10.

Google Scholar 

Wolf M, Rubin J, Achebe M, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA - J Am Med Assoc. 2020;323(5):432–43.

Google Scholar 

Fragkos KC, Sehgal V, Rogers J, et al. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose—Real world experience from a tertiary centre in the UK. GastroHep. 2020;2(5):205–14.

Google Scholar 

Brunelli SM, Goldfarb S. Hypophosphatemia. J Am Soc Nephrol. 2007;18(7):1999–2003.

CAS  PubMed  Google Scholar 

Imel EA, Econs MJ. Approach to the Hypophosphatemic Patient. J Clin Endocrinol Metab. 2012;97(3):696–706.

CAS  PubMed  PubMed Central  Google Scholar 

Zoller H, Wolf M, Blumenstein I, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644–53.

CAS  PubMed  Google Scholar 

Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833–42.

CAS  PubMed  Google Scholar 

Goodnough LT, Van Wyck DB, Mangione A, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009;49(12):2719–28.

PubMed  Google Scholar 

Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007–14.

CAS  PubMed  PubMed Central  Google Scholar 

Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-853.e2.

CAS  PubMed  Google Scholar 

Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynecol Obstet. 2016;133(1):43–8.

CAS  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. National Cancer Institute; 2010.

Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. National Cancer Institute; 2017.

Schaefer B, Glodny B, Wolf M, et al. Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. Aliment Pharmacol Ther. 2017;46(6):641–3.

CAS  PubMed  Google Scholar